Please login to the form below

Not currently logged in
Email:
Password:

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Offers €15m upfront for the anti-SIRP-alpha antibody and €15m when it reaches phase I testing

BI

Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than €1.1bn (around $1.4bn).

The deal focuses around OSE-172, an anti-SIRP-alpha antibody with potential in solid tumours that is currently in preclinical development. Boehringer is stumping up €15m upfront, with another €15m due when the antibody starts phase I testing and another €1.1bn on offer if it makes it through to market and hits sales targets.

Research suggests that antibodies blocking the interaction of SIRP-alpha and CD47 receptors can enhance tumour-killing and rejection, in part by activating cytotoxic T lymphocytes (CTL) responses. Other companies developing drugs against that pathway include US startup Forty Seven, Trillium Therapeutics, and Aurigene, with all those programmes in early development.

Boehringer has a relatively short heritage in cancer - starting its oncology R&D programme in 2006 and launching its first product in 2012. It is also something of a late entrant to the cancer immunotherapy category, but has started to build a presence in recent years, both via in-house R&D and also through external collaborations. For instance, it licensed CureVac’s cancer vaccine CV9202 in 2014, formed a collaboration with Philogen seeking immunotherapies for acute myeloid leukaemia in 2015, and partnered an oncolytic virus therapy developed by ViraTherapeutics in 2016.

The company that that the OSE collaboration “strengthens a core pillar of [our] cancer immunology and immune modulation strategy focusing on novel approaches to treat cancer”.

A key focus of that effort is to find drugs that target myeloid cell immune regulatory receptors “of which SIRP-alpha is a leading example”, commented Jonathon Sedgwick, Boehringer’s head of cancer immunology and immune modulation research.

For OSE, the deal gives it another partnership with a large pharma partner, adding to collaborations with Memorial Sloan Kettering Cancer Centre in the US and biotech Selexis on immuno-oncology, and two alliances in the area of autoimmune diseases and transplantation. The latter are with Servier on interleukin-7 inhibitor OSE-127 and with Johnson & Johnson’s Janssen Biotech unit for FR104, a CD28-antagonist.

Article by
Phil Taylor

10th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics